Literature DB >> 21461668

Dementia in Parkinson's disease.

Avrom L Kurtz1, Daniel I Kaufer.   

Abstract

OPINION STATEMENT: Dementia in Parkinson's disease encompasses a spectrum relating to motor, psychiatric, and cognitive symptoms that are classified as either Dementia with Lewy Bodies (DLB) (initial cognitive symptoms) or Parkinson's Disease Dementia (PDD) (initial motor signs preceding cognitive symptoms by at least a year). Anticholinergic and antipsychotic drugs have a high risk of adverse cognitive and/or motor effects, so their use should be minimized or avoided. Neuroleptic sensitivity is a severe psychomotor adverse reaction that is particularly associated with potent dopamine-blocking agents such as haloperidol. It occurs in up to 50% of individuals with PDD or DLB. Mild psychotic symptoms should first be addressed by reducing anticholinergic and/or dopaminergic agents, if possible. Patients with psychotic symptoms that threaten the safety of the patient or caregiver may benefit from treatment with quetiapine or, in refractory cases, clozapine. Cholinesterase inhibitors as a drug class have been shown to have beneficial effects on cognition in DLB and PDD, and may help to alleviate some psychiatric symptoms, such as apathy, anxiety, hallucinations, and delusions. Memantine may help to moderate cognitive symptoms in DLB and PDD, although current data suggest a more variable response, particularly in PDD. Parkinsonian motor signs that are accompanied by clinically significant cognitive impairment should be treated with carbidopa/levodopa only, as dopamine agonists and other antiparkinsonian medications generally carry a higher risk of provoking or exacerbating psychotic symptoms. Excessive daytime sleepiness and REM sleep behavior disorder are common associated features of PDD and DLB. Minimizing sedating medications during the day and promoting nocturnal sleep may help the daytime sleepiness; melatonin, clonazepam, gabapentin, and possibly memantine may be useful in treating REM sleep behavior disorder. Orthostatic hypotension can be managed with various nonpharmacologic interventions, and if needed, fludrocortisone and pyridostigmine. Midodrine should be used cautiously, if at all.

Entities:  

Year:  2011        PMID: 21461668     DOI: 10.1007/s11940-011-0121-1

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  54 in total

1.  Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial.

Authors:  B Högl; M Saletu; E Brandauer; S Glatzl; B Frauscher; K Seppi; H Ulmer; G Wenning; W Poewe
Journal:  Sleep       Date:  2002-12       Impact factor: 5.849

Review 2.  Parkinson's disease psychosis 2010: a review article.

Authors:  Joseph H Friedman
Journal:  Parkinsonism Relat Disord       Date:  2010-06-09       Impact factor: 4.891

3.  Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease.

Authors:  William G Ondo; Ron Tintner; Kevin Dat Voung; Dejian Lai; George Ringholz
Journal:  Mov Disord       Date:  2005-08       Impact factor: 10.338

Review 4.  Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management.

Authors:  Kristian Winge; Clare J Fowler
Journal:  Mov Disord       Date:  2006-06       Impact factor: 10.338

5.  Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease.

Authors:  Charles H Adler; John N Caviness; Joseph G Hentz; Marlene Lind; Judy Tiede
Journal:  Mov Disord       Date:  2003-03       Impact factor: 10.338

6.  Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study.

Authors:  Keith Edwards; Donald Royall; Linda Hershey; David Lichter; Ann Hake; Martin Farlow; Florence Pasquier; Stewart Johnson
Journal:  Dement Geriatr Cogn Disord       Date:  2007-04-03       Impact factor: 2.959

7.  Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study.

Authors:  D Aarsland; K Laake; J P Larsen; C Janvin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-06       Impact factor: 10.154

8.  Montreal cognitive assessment performance in patients with Parkinson's disease with "normal" global cognition according to mini-mental state examination score.

Authors:  Sarra Nazem; Andrew D Siderowf; John E Duda; Tom Ten Have; Amy Colcher; Stacy S Horn; Paul J Moberg; Jayne R Wilkinson; Howard I Hurtig; Matthew B Stern; Daniel Weintraub
Journal:  J Am Geriatr Soc       Date:  2008-12-10       Impact factor: 5.562

9.  Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study.

Authors:  William G Ondo; Thomas Perkins; Todd Swick; Keith L Hull; J Ernesto Jimenez; Tippy S Garris; Daniel Pardi
Journal:  Arch Neurol       Date:  2008-10

10.  Antipsychotic drug use and mortality in older adults with dementia.

Authors:  Sudeep S Gill; Susan E Bronskill; Sharon-Lise T Normand; Geoffrey M Anderson; Kathy Sykora; Kelvin Lam; Chaim M Bell; Philip E Lee; Hadas D Fischer; Nathan Herrmann; Jerry H Gurwitz; Paula A Rochon
Journal:  Ann Intern Med       Date:  2007-06-05       Impact factor: 25.391

View more
  4 in total

Review 1.  Lewy Body Disease: Clinical and Pathological "Overlap Syndrome" Between Synucleinopathies (Parkinson Disease) and Tauopathies (Alzheimer Disease).

Authors:  Clovis Foguem; Patrick Manckoundia
Journal:  Curr Neurol Neurosci Rep       Date:  2018-04-08       Impact factor: 5.081

2.  Predictors of mild cognitive impairment in early-stage Parkinson's disease.

Authors:  Brenda Hanna-Pladdy; Katherine Jones; Romeo Cabanban; Rajesh Pahwa; Kelly E Lyons
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2013-05-18

3.  Cognitive effects of dopamine depletion in the context of diminished acetylcholine signaling capacity in mice.

Authors:  Lilia Zurkovsky; Evgeny Bychkov; Elviche L Tsakem; Carley Siedlecki; Randy D Blakely; Eugenia V Gurevich
Journal:  Dis Model Mech       Date:  2012-08-03       Impact factor: 5.758

4.  ASMT gene expression correlates with cognitive impairment in patients with recurrent depressive disorder.

Authors:  Monika Talarowska; Janusz Szemraj; Marlena Zajączkowska; Piotr Gałecki
Journal:  Med Sci Monit       Date:  2014-06-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.